Comparison 3. Bamlanivimab compared to placebo to prevent COVID‐19 (postexposure prophylaxis).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Infection with SARS‐CoV‐2 by day 30	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.2 All‐cause mortality by day 60	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.3 Adverse events: all grade	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.4 Serious adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected